Covidien (COV) plans to spin off its pharma business into a standalone public company. At...

|By:, SA News Editor

Covidien (COV) plans to spin off its pharma business into a standalone public company. At present, the pharma unit accounts for $2B of sales. Post-split, Covidien's medical products business will generate around $9.6B in sales. (PR)